IL-12-producing cytokine factories induce precursor exhausted T cells and elimination of primary and metastatic tumorsAmanda Nash, Omid Veiseh, Jonathon DeBonis et al.|Journal for ImmunoTherapy of Cancer|2025Cited by 10
Uncovering the interleukin‐12 pharmacokinetic desensitization mechanism and its consequences with mathematical modelingJonathon DeBonis, Oleg A. Igoshin, Omid Veiseh|CPT Pharmacometrics & Systems Pharmacology|2024Cited by 5
Factors influencing monoclonal antibody pharmacokinetics across varying immune perturbationsJonathon DeBonis, Omid Veiseh, Zeshi Wang et al.|Journal of Controlled Release|2025Cited by 4
Uncovering the Interleukin-12 Pharmacokinetic Desensitization Mechanism and Its Consequences with Mathematical ModelingJonathon DeBonis, Oleg A. Igoshin, Omid Veiseh|bioRxiv (Cold Spring Harbor Laboratory)|2024Cited by 1
Supplementary Figure S1 from First-In-Human Trial of Encapsulated Cells Constitutively Expressing Localized IL2 in Patients with High-Grade Serous Ovarian CarcinomaHelen Clark, Shannon N. Westin, Samira Aghlara-Fotovat et al.|Unknown|2026Cited by 0